Results 21 to 30 of about 424,058 (165)

Three-month antibody persistence of a bivalent Omicron-containing booster vaccine against COVID-19

Nature Communications, 2023
We previously presented day 29 interim safety and immunogenicity results from a phase 2/3 study (NCT04927065) comparing the Omicron-BA.1-containing bivalent vaccine mRNA-1273.214 (50-µg) to the 50-µg mRNA-1273 booster in adults who previously received ...
Spyros Chalkias, Charles Harper, Keith Vrbicky, Stephen R. Walsh, Brandon Essink, Adam Brosz, Nichole McGhee, Joanne E. Tomassini, Xing Chen, Ying Chang, Andrea Sutherland, David C. Montefiori, Bethany Girard, Darin K. Edwards, Jing Feng, Honghong Zhou, Lindsey R. Baden, Jacqueline M. Miller, Rituparna Das   +18 more
doaj   +1 more source

Myocarditis following COVID‐19 mRNA (mRNA‐1273) vaccination

Clinical Case Reports, 2022
In this case report, we presented a case of myocarditis as a rare complication that developed after Covid mRNA‐1273 vaccine. Cases of post‐vaccine myocarditis usually progress with mild symptoms.
Suresh Babu Chellapandian, Suha Turkmen, Imtiaz Salim, Shanmugavel Chinnakaruppan, Jassim Mohammad   +4 more
doaj   +1 more source

Trajectory of IgG to SARS-CoV-2 After Vaccination With BNT162b2 or mRNA-1273 in an Employee Cohort and Comparison With Natural Infection

Frontiers in Immunology, 2022
Three COVID-19 vaccines have received FDA-authorization and are in use in the United States, but there is limited head-to-head data on the durability of the immune response elicited by these vaccines.
Behnam Keshavarz, Nathan E. Richards, Lisa J. Workman, Jaimin Patel, Lyndsey M. Muehling, Glenda Canderan, Deborah D. Murphy, Savannah G. Brovero, Samuel M. Ailsworth, Will H. Eschenbacher, Emily C. McGowan, Barbara J. Mann, Michael R. Nelson, Alexandra Kadl, Alexandra Kadl, Judith A. Woodfolk, Thomas A.E. Platts-Mills, Jeffrey M. Wilson   +17 more
doaj   +1 more source

Postmarketing active surveillance of myocarditis and pericarditis following vaccination with COVID-19 mRNA vaccines in persons aged 12 to 39 years in Italy: A multi-database, self-controlled case series study.

PLoS Medicine, 2022
BackgroundMyocarditis and pericarditis following the Coronavirus Disease 2019 (COVID-19) mRNA vaccines administration have been reported, but their frequency is still uncertain in the younger population.
Marco Massari, Stefania Spila Alegiani, Cristina Morciano, Matteo Spuri, Pasquale Marchione, Patrizia Felicetti, Valeria Belleudi, Francesca Romana Poggi, Marco Lazzeretti, Michele Ercolanoni, Elena Clagnan, Emanuela Bovo, Gianluca Trifirò, Ugo Moretti, Giuseppe Monaco, Olivia Leoni, Roberto Da Cas, Fiorella Petronzelli, Loriana Tartaglia, Nadia Mores, Giovanna Zanoni, Paola Rossi, Sarah Samez, Cristina Zappetti, Anna Rosa Marra, Francesca Menniti Ippolito, TheShinISS-Vax|COVID Surveillance Group   +26 more
doaj   +1 more source

Humeral and cellular immune responses to SARS-CoV-2 vaccination in patients on peritoneal dialysis

Journal of the Formosan Medical Association, 2023
Background: Patients with chronic kidney disease are at high risk for coronavirus disease 2019. Little is known about immune response to severe acute respiratory syndrome coronavirus 2 vaccination in patients on peritoneal dialysis (PD).
Zhi-Ye Yu, Chun-Fu Lai, Tai-Shuan Lai, Shao-Yu Yang, Shih-I Chen, Mei-Jun Lai, Chun-Min Kang, Yu-Tsung Huang, Yi-Ting Chen, Po-Ren Hsueh, Yung-Ming Chen, Shuei-Liong Lin   +11 more
doaj   +1 more source

Comparative 6-Month Wild-Type and Delta-Variant Antibody Levels and Surrogate Neutralization for Adults Vaccinated with BNT162b2 versus mRNA-1273

Microbiology Spectrum, 2022
While mRNA vaccines are highly efficacious against short-term COVID-19, long-term immunogenicity is less clear. We compared humoral immunogenicity between BNT162b2 and mRNA-1273 vaccines 6 months after the first vaccine dose, examining the wild-type ...
Brian Grunau, Liam Golding, Martin A. Prusinkiewicz, Michael Asamoah-Boaheng, Richard Armour, Ana Citlali Marquez, Agatha N. Jassem, Vilte Barakauskas, Sheila F. O’Brien, Steven J. Drews, Scott Haig, Pascal M. Lavoie, David M. Goldfarb   +12 more
doaj   +1 more source

Antibody response after a third dose mRNA-1273 vaccine among vaccinated healthcare workers with two doses of inactivated SARS-CoV-2 vaccine

International Journal of Infectious Diseases, 2022
Background: Health care workers (HCWs), a high-risk group for contracting COVID-19 disease, are being prioritized to receive COVID-19 vaccination. A third dose messenger RNA (mRNA) vaccine, mRNA-1273 (Moderna), after 2 doses of inactivated vaccine ...
Cucunawangsih Cucunawangsih, Ratna Sari Wijaya, Nata Pratama Hardjo Lugito, Ivet Suriapranata   +3 more
doaj   +1 more source

mRNA-1273 elicits higher NAb responses in treatment-naïve CLL vaccinees.

, 2023
(A) ID50 neutralizing titers against the SARS-CoV-2 D614G and Delta variants in all CLL patients who received either the BNT162b2 or the mRNA-1273 vaccine.
Kai Qin (293713), Anju Bansal (56201), Randall S. Davis (8450517), Weimin Liu (50340), Sarah Sterrett (161415), Kazuhito Honjo (8450493), Victor M. Cruz Portillo (16469335), Benjamin M. Larimer (14928039), Mayur Narkhede (3826087), Regina M. Stoltz (16469317), Jeffrey R. Lancaster (1932982), Foluso J. Ogunsile (16469329), Paul A. Goepfert (7181315), Ellen R. Frederick (16469326), Allisa K. Oman (16469320), Rima B. Patel (16469332), Lucinda A. Hall (16469323), Ran Li (57928), Amitkumar Mehta (800257), Beatrice H. Hahn (8157399), Thomas J. Ketas (460721), Scott Sherrill-Mix (692150), Albert Cupo (409522)   +22 more
core   +1 more source

Antibody Response in Immunocompromised Patients After the Administration of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine BNT162b2 or mRNA-1273: A Randomized Controlled Trial [PDF]

, 2022
BACKGROUND BNT162b2 by Pfizer-BioNTech and mRNA-1273 by Moderna are the most commonly used vaccines to prevent SARS-CoV-2 infections. Head-to-head comparison of the efficacy of these vaccines in immunocompromised patients is lacking.
Trkola, A., Eichenberger, Anna L, Günthard, Huldrych F, Speich, Benjamin, Audigé, A., Chammartin, Frédérique, Mueller, N.J., Koller, Michael T, Tamm, M., Schuurmans, Macé M, Stoeckle, M.P., Trkola, Alexandra, Amico, P., Audigé, Annette, Rauch, A., Bucher, Heiner C, Chammartin, F., Abela, I.A., Braun, Dominique L, Mueller, Nicolas J, Swiss HIV Cohort Study, Swiss Transplant Cohort Study, Amico, Patrizia, Speich, B., Hasse, Barbara, Koller, M.T., Kusejko, K., Tamm, Michael, Rauch, Andri, Müller, Thomas F, Braun, D.L., Briel, M., Günthard, H.F., Schuurmans, M.M., Stoeckle, Marcel P, Kusejko, Katharina, Hasse, B., Briel, Matthias, Bucher, H.C., Müller, T.F., Eichenberger, A.L., Abela, Irene A   +41 more
core   +1 more source

Serological response after COVID-19 mRNA-1273 booster dose in immunocompromised patients, Taiwan, July to August 2021

Journal of the Formosan Medical Association, 2022
Background: Whether immunocompromising conditions affect the immunogenicity of COVID-19 booster vaccination remains a concern, which impedes the vaccination campaign in people most vulnerable to COVID-19-associated morbidity and mortality.
Kuan-Yin Lin, Ming-Ju Hsieh, Sui-Yuan Chang, Si-Man Ieong, Chien-Yu Cheng, Wang-Huei Sheng, Shan-Chwen Chang   +6 more
doaj   +1 more source